Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 2, 2008 Steven Renaldi	Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
The Motley Fool May 6, 2008 Steven Renaldi	McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
InternetNews October 13, 2004 Roy Mark	Report: The Internet and Drugs Don't Mix It seems an increasing number of Americans are researching drugs online, but safety fears chill buying.
The Motley Fool October 8, 2007 Billy Fisher	McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note.
The Motley Fool September 30, 2008 Brian Orelli	Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business?
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
Chemistry World May 2, 2014 Phillip Broadwith	Forest Labs buys Furiex for bowel drug Forest Laboratories has agreed to buy Furiex pharmaceuticals for $1.1 billion in cash, with a top-up of up to $360 million contingent on approval of Furiex's irritable bowel syndrome drug eluxadoline.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
BusinessWeek November 24, 2003 Roger O. Crockett	Cardinal Health, Heal Thyself CEO Walter aims to revive growth, selling high-tech gear and expanding overseas.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool June 13, 2006 Ryan Fuhrmann	Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment.
The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool October 28, 2004 Brian Gorman	Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K.
The Motley Fool January 12, 2010 Dayana Yochim	6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
Chemistry World March 23, 2010	Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
The Motley Fool November 2, 2007 Brian Lawler	A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note.
The Motley Fool May 20, 2004 Tom Taulli	Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth.
Reason January 2004 Jacob Sullum	Seed Case First the Drug Enforcement Administration tried to ban hemp foods by claiming they've been illegal for three decades; it's just that no one noticed until recently. In June the U.S. Court of Appeals for the 9th Circuit rejected that gambit, forcing the DEA to issue new regulations.
Reason September 2004 Maia Szalavitz	Dr. Feelscared U.S. drug warriors put the fear of prosecution in physicians who dare to treat pain. While the OxyContin panic does not seem to have deterred addicts, it has scared doctors.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
Chemistry World June 26, 2013 Emma Stoye	UN report warns of global rise in legal highs The latest World Drug Report from the United Nations Office on Drugs and Crime says governments around the world are struggling to cope with a growing number of legal party drugs.
The Motley Fool August 3, 2006 Ryan Fuhrmann	Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC.
The Motley Fool October 17, 2010 Joseph Picard	CVS Gets Smurfed and Fined The DEA accuses CVS drugstore chain of helping fuel meth production.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 30, 2006 Brian Gorman	Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note.
Chemistry World March 3, 2015 Phillip Broadwith	J&J to sell cardiac devices to wholesaler Cardinal Johnson & Johnson has agreed to sell its cardiovascular surgical devices subsidiary, Cordis, to wholesale supplier Cardinal Health.
The Motley Fool September 2, 2009 Brian Orelli	Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest.
Reason February 2005 Jacob Sullum	Disappearing Docs Doctors have been fighting the "opiophobia" that leads to widespread undertreatment of pain for many years. But it was surprising to see them endorsed by the DEA, which has long insisted there is no conflict between drug control and pain control.
American Family Physician March 15, 2004	Substance Abuse Questions and answers on substance abuse.
Chemistry World April 30, 2014 Emma Stoye	New Zealand in legal highs U-turn Politicians in New Zealand have decided to ban designer drugs from sale in the country, reversing an earlier decision to approve low risk drugs while new laws are put in place.
The Motley Fool July 28, 2004 Brian Gorman	Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge.
Reason January 2005 Jacob Sullum	Medicinal Grass Despite marijuana's low toxicity and long history of medicinal use, federal law puts it in a highly restrictive category. After decades of unsuccessful attempts to correct this anomaly, medical marijuana activists are trying a less direct approach.
Reason October 2005 Daniel Koffler	Honest Agents At DEA Watch, anonymous narcs gather to share rather disturbing musings on politics and American public policy.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
BusinessWeek August 30, 2004 Gene G. Marcial	PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell.